Translational Research Network for Prostate Cancer (TransPot)
Today starts Movember (a combination of the English diminutive word for moustache, “mo”, and “November”), an annual event involving the growing of moustaches during the month of November to raise awareness of men’s health issues, such as prostate cancer, testicular cancer and men’s suicide. Prostate cancer is one of the most prevalent cancer types in Europe. Early diagnosis, active surveillance and appropriate treatments have improved the quality of care. Although prostate cancer can be treated successfully, incurable forms of the disease remain.
The Translational Research Network for Prostate Cancer (TransPot) is a European program designed to tackle therapy-resistant prostate cancer (PCa). TransPot is a cross-disciplinary research network aimed at deepening the understanding of lethal prostate cancer in order to improve the prognosis and treatment of patients. The TransPot consortium offers a research program designed to train 11 Early Stage Researchers (ESRs) through a collaboration between academic, private and clinical sectors.
GenomeScan is one of the companies participating in TransPot. In our R&D department, we welcome 2 talented ESRs, Ingrid Tomljanovic and Mario Cangiano working on the integration of different data types from preclinical models for biomarker discovery and validation, as well as on the elucidation of gene regulatory mechanisms in castration-resistant prostate cancer. Both ESRs exploit machine learning pipelines to extract insights from next generation sequencing and high-throughput biological data. Their aim is to discover new therapeutic targets and develop better treatment strategies to support personalized medicine in patients with lethal prostate cancer.
On a regular basis, members of the program exchange information on the progress of their research, follow lectures or participate in interactive training courses. In a following blog, Ingrid Tomljanovic will report on the biannual meeting that took place in October.